Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation

Biotechnology and Bioengineering

Volumn 114, Issue 4, 2017, Pages 813-820

  Conley, Lynn ^a   Tao, Yinying ^b   Henry, Alexis ^a   Koepf, Edward ^a   Cecchini, Douglas ^a   Pieracci, John ^a   Ghose, Sanchayita ^a  

^a BIOGEN   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

detergent; enveloped virus inactivation; LDAO; protein purification; Triton X 100

Indexed keywords

AFFINITY CHROMATOGRAPHY; AQUATIC ORGANISMS; CELL CULTURE; CHROMATOGRAPHY; CRITICAL MICELLE CONCENTRATION; DETERGENTS; ENDOCRINE DISRUPTERS; ENVIRONMENTAL IMPACT; ENVIRONMENTAL PROTECTION; PURIFICATION; SOAPS (DETERGENTS); VIRUSES; WASTE TREATMENT; WASTEWATER TREATMENT; WATER TREATMENT;

CRITICAL MICELLE CONCENTRATION (CMC); ENVELOPED VIRUS; IDENTIFICATION AND EVALUATION; LDAO; PROTEIN CONCENTRATIONS; PROTEIN PURIFICATION; TRITON X-100; ZWITTERIONIC DETERGENTS;

PROTEINS;

DETERGENT; LAURYLDIMETHYLAMINE N OXIDE; POLIDOCANOL; PROTEIN A; SULFOBETAINE 3 12; SULFOBETAINE 3 14; SULFOBETAINE 3 16; TRITON X 100; UNCLASSIFIED DRUG; DIMETHYLAMINE; DODECYLDIMETHYLAMINE OXIDE; OCTOXINOL;

ANTIVIRAL ACTIVITY; AQUATIC SPECIES; ARTICLE; CRITICAL MICELLE CONCENTRATION; DOWNSTREAM PROCESSING; ECOTOXICITY; ENVIRONMENTAL HEALTH; ENVIRONMENTAL IMPACT; GAS CHROMATOGRAPHY; IN VITRO STUDY; MURINE LEUKEMIA VIRUS; NONHUMAN; PROTEIN PURIFICATION; PROTEIN STABILITY; PSEUDORABIES VIRUS; VIRAL CLEARANCE; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS SPIKE; WASTE WATER TREATMENT PLANT; CHEMISTRY; DRUG EFFECTS; GREEN CHEMISTRY; MOLECULAR MODEL;

DETERGENTS; DIMETHYLAMINES; GREEN CHEMISTRY TECHNOLOGY; HERPESVIRUS 1, SUID; LEUKEMIA VIRUS, MURINE; MODELS, MOLECULAR; OCTOXYNOL; VIRUS INACTIVATION;

EID: 85001754510     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.26209     Document Type: Article

References (43)

1. Aranha H. 2012. Current issues in assuring virological safety of biopharmaceuticals. BioProcess Int 10(3):12–17.
2. Arnold T, Linke D. 2007. Phase separation in the isolation and purification of membrane proteins. Biotechniques 43(4):427–440.
3. Bertrand I, Schijven J, Sánchez G, Wyn-Jones P, Ottoson J, Morin T, Muscillo M, Verani M, Nasser A, de Roda Husman A, Myrmel M, Sellwood J, Cook N, Gantzer C. 2012. The impact of temperature on the inactivation of enteric viruses in food and water: A review. J Appl Microbiol 112(6):1059–1074.
4. Boschetti N, Wyss K, Mischler A, Hostettler T, Kempf C. 2003. Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals 31(3):181–185.
5. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. 2003. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82(3):321–329.
6. Buss N, Henderson S, McFarlane M, Shenton J, de Haan L. 2012. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol 12(5):615–622.
7. Cameron R, Smith K. 2014. Virus clearance methods applied in bioprocessing operations: An overview of selected inactivation and removal methods. Pharm Bioprocess 2(1):75–83.
8. Chadd H, Chamow S. 2001. Therapeutic antibody expression technology. Curr Opin Biotechnol 12(2):188–194.
9. Chen H-J, Tseng D-H, Huang S-L. 2005. Biodegradation of octophenol polyethoxylate surfactant Triton X-100 by selected microorgansims. Bioresour Technol 96(13):1483–1491.
10. Cuatrecasas P. 1972. Isolation of the insulin receptor of liver and fat-cell membranes. Proc Nat Acad Sci USA 69(2):318–322.
11. Davidoff C, Payne R, Willis S, Doranz B, Rucker J. 2012. Maturation of the Gag core decreases the stability of retroviral lipid membranes. Virology 433(2):401–409.
12. Ecker D, Jones S, Levine H. 2015. The therapeutic monoclonal antibody market. mAbs 7(1):9–14.
13. Ejima D, Tsumoto K, Fukada H, Yumioka R, Nagase K, Arakawa T, Philo J. 2007. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 66(4):954–962.
14. Farshid M, Taffs R, Scott D, Asher D, Brorson K. 2005. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 16(5):561–567.
15. Garavito R, Ferguson-Miller S. 2001. Detergents as tools in membrane biochemistry. J Biol Chem 276(35):32403–32406.
16. Heerklotz H, Seelig J. 2000. Correlation of membrane/water partition coefficients of detergents with the critical micelle concentration. Biophys J 78(5):2435–2440.
17. Helenius A, Simons K. 1975. Solubilization of membranes by detergents. Biochim Biophys Acta 415(1):29–79.
18. Henriksen J, Andresen T, Feldborg L, Duelund L, Ipsen J. 2010. Understanding detergent effects on lipid membranes: A model study of lysolipids. Biophys J 98(10):2199–2205.
19. Herrmann K. 1962. Non-ionic-cationic micellar properties of dimethyldodecylamine oxide. J Phys Chem 66(2):295–300.
20. Hesse F, Wagner R. 2000. Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends Biotechnol 18(4):173–180.
21. Horowitz B, Bonomo R, Prince A, Chin S, Brotman B, Shulman R. 1992. Solvent/detergent-treated plasma: A virus-inactvated substitute for fresh frozen plasma. Blood 79(3):826–831.
22. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. 1998. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 74(S1):203–206.
23. Kerr A, Nims R. 2010. Adventitious viruses detected in biopharmaceutical bulk harvest samples over a 10 year period. PDA J Pharm Sci Technol 64(5):481–485.
24. Koynova R, Tenchov B. 2001. Interactions of surfactants and fatty acids with lipids. Curr Opin Colloid Interface Sci 6(3):277–286.
25. Lasch J. 1995. Interaction of detergents with lipid vesicles. Biochim Biophys Acta 1241(2):269–292.
26. le Maire M, Champeil P, Møller J. 2000. Interaction of membrane proteins and lipids with solubilizing detergents. Biochim Biophys Acta 1508(1):86–111.
27. McCue J, Selvitelli K, Cecchini D, Brown R. 2014. Enveloped virus inactivation using neutral arginine solutions and applications in therapeutic protein purification processes. Biotechnol Prog 30(1):108–112.
28. Miesegaes G, Lute S, Strauss D, Read E, Venkiteshwaran A, Kreuzman A, Shah R, Shamlou P, Chen D, Brorson K. 2012. Monoclonal antibody capture and viral clearance by cation exchange chromatography. Biotechnol Bioeng 109(8):2048–2058.
29. Nelson A, Dhimolea E, Reichert J. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767–774.
30. Nimrod A, Benson W. 1996. Environmental estrogenic effects of alkylphenol ethoxylates. Crit Rev Toxicol 26(3):335–364.
31. Piët M, Chin S, Pprince A, Brotman B, Cundell A, Horowitz B. 1990. The use of tri(n-buty1)phosphate (TNBP) detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and its subsequent fractionation. Transfusion 30(7):591–598.
32. Privé G. 2007. Detergents for the stabilization and crystallization of membrane proteins. Methods 41(4):388–397.
33. Remington K. 2015. Fundamental strategies for viral clearance. BioProcess Int 13(5):10–17.
34. Roberts P. 2008. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII. Biologicals 36(5):330–335.
35. Roberts P, Lloyd D, Marshall P. 2009. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20. Biologicals 37(1):26–31.
36. Schik M. 1963. Effect of temperature on the critical micelle concentration of nonionic detergents. Thermodynamics of micelle formation. J Phys Chem 67(9):1796–1799.
37. Shukla A, Aranha H. 2015. Viral clearance for biopharmaceutical downstream processes. Pharm Bioprocess 3(2):127–138.
38. Shukla A, Thömmes J. 2010. Recent advances in large-scale production of monoclonal antibodies and releated proteins. Trends Biotechnol 28(5):253–261.
39. Tanford C, Nozaki Y, Reynolds J, Makino S. 1974. Molecular characterization of proteins in detergent solutions. Biochemistry 13(11):2369–2376.
40. Umbreit J, Strominger J. 1973. Relation of detergent HLB number to solubilization and stabilization of D-alanine carboxypeptidase from Bacillus subtilis membranes. Proc Nat Acad Sci USA 70(10):2997–3001.
41. Walsh G. 2014. Biopharmaceutical benchmarks 2014. Nat Biotechnol 32(10):992–1000.
42. Westoby M, Chrostowski J, de Vilmorin P, Smelko J, Romero J. 2010. Effects of solution environment on mammalian cell fermenation broth properties: Enhanced impurity removal and clarification performance. Biotechnol Bioeng 108(1):50–58.
43. Zhou J. 2009. Orthogonal virus clearance applications in monoclonal antibody production. In: Gottschalk U, editor. Process scale purification of antibodies. Hoboken, NJ: John Wiley & Sons. p 169–186.